ArticleBMC neurology2026
Severe peripheral neuropathy secondary to acute intermittent porphyria caused by a rare HMBS gene mutation: a case report.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeripheral neuropathy is caused by numerous etiologies, such as immune, infectious, neoplastic, metabolic, toxic, traumatic, vasculitic, hereditary factors, etc. Each etiological type has no special manifestation, and the misdiagnosis rate is relatively high. Acute intermittent porphyria (AIP) is a rare disease, often complicated by peripheral nerve injury, and can develop sequelae after delayed diagnosis or treatment. CASE PRESENTATION: A 26-year-old female patient presented with recurrent abdominal pain, limb numbness and weakness, and autonomic neuropathy. Symptoms aggravated and respiratory and circulatory failure develop gradually, following the recurrence of the disease. She was initially diagnosed with neurosis, intestinal obstruction, and Guillain-Barré syndrome. She underwent treatment for inflammatory peripheral neuropathy, including intravenous immunoglobulin (IVIG) and plasmapheresis; however, no improvement in symptoms was observed. Clinical assessment revealed brown urine that turned reddish-brown after sunlight exposure. Whole exome sequencing (WES) identified a mutation in the HMBS gene (exon 10, c.651G > C, p.Gln217His), which was confirmed through Sanger sequencing and diagnosed as rare AIP with severe peripheral nerve damage. Numbness and weakness gradually improved after the initiation of hemin therapy and high-carbohydrate therapy.
conclusionThe AIP is an easily missed or misdiagnosed disease. In the absence of timely and effective intervention, patients are at risk of developing irreversible and permanent neurological damage. It is essential for clinicians to enhance their awareness of the disease to ensure prompt diagnosis, appropriate treatment, and avoidance of triggering factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.